• Thirty-three patients with diffuse non-Hodgkin's lymphoma (stages I and II) received intermediate doses of oral methotrexate followed by leucovorin calcium every four weeks, on days 1 and 8, followed on day 15 by intravenous cyclophosphamide and vincristine sulfate. Prednisone was given for four weeks on alternate courses of treatment. A total of six such four-week courses was planned. Involved-field radiation (3000 or 3600 rad [30 or 36 Gy]) was given between three courses of chemotherapy to 18 patients who presented with tumors exceeding 7 cm in greatest diameter and who had responded to the initial chemotherapy. On completion of treatment, 27 patients (82%) were in complete remission; all the failures were in patients with large intra-abdominal masses. The presence of high lactate dehydrogenase levels, large tumor size, and age over 60 years had a suggestive negative correlation with the achievement of complete remission. The median follow-up was 26 months (range, ten to 59 months). At 48 months, the actuarial disease-free survival, remission duration, and overall survival were 53%, 72%, and 68% respectively. No deaths from toxic effects and no septic episodes were observed during treatment. The complete remission rate achieved with this program is comparable with those of other intensive programs of treatment reported previously.
(Arch Intern Med 1986;146:1785-1788)
Gomez GA, Reddy S, Krishnamsetty RM, et al. Primary Chemotherapy for Localized Non-Hodgkin's Lymphomas With Diffuse Histologic Characteristics: Preliminary Report of a Prospective Study. Arch Intern Med. 1986;146(9):1785–1788. doi:10.1001/archinte.1986.00360210171024
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.